76 related articles for article (PubMed ID: 2050596)
1. In-vitro and in-vivo antimicrobial activities of a novel cephalosporin derivative, CP6162, possessing a dihydroxypyridone moiety at the C-3 side chain.
Orikasa Y; Hara T; Miyata A; Tamura A; Kawaharajo K; Matsumoto T; Komiya I; Iwamatsu K; Shibahara S; Inouye S
J Antimicrob Chemother; 1991 Jan; 27(1):41-53. PubMed ID: 2050596
[TBL] [Abstract][Full Text] [Related]
2. In vitro antimicrobial activity of a novel aminothiazolylglycylcephalosporin, MT0703S, compared with that of ceftazidime, cefoperazone and aztreonam.
Okamoto R; Hara T; Yoshida T; Orikasa Y; Ogino H; Iwamatsu K; Inouye S
Drugs Exp Clin Res; 1990; 16(4):157-65. PubMed ID: 2127567
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
Inoue K; Inoue E; Mitsuhashi S
Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.
Neu HC; Chin NX; Saha G; Labthavikul P
Antimicrob Agents Chemother; 1986 Dec; 30(6):828-34. PubMed ID: 3545068
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activities of ME1220 and ME1221, novel cephalosporins.
Okamoto R; Tamura A; Yoshida T; Komiya I; Ogino H; Inouye S; Kondo S; Inoue M; Mitsuhashi S
Drugs Exp Clin Res; 1991; 17(4):205-12. PubMed ID: 1794294
[TBL] [Abstract][Full Text] [Related]
7. In-vitro antibacterial activity of DQ-2556 and its stability to various beta-lactamases.
Fujimoto T; Watanabe M; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Sep; 26(3):329-41. PubMed ID: 2228824
[TBL] [Abstract][Full Text] [Related]
8. Biological activity of BO-1236, a new antipseudomonal cephalosporin.
Nakagawa S; Sanada M; Matsuda K; Hazumi N; Tanaka N
Antimicrob Agents Chemother; 1987 Jul; 31(7):1100-5. PubMed ID: 3116919
[TBL] [Abstract][Full Text] [Related]
9. The in vitro activity of sulbactam combined with third generation cephalosporins against third generation cephalosporin-resistant bacteria.
Zhang YL; Li JT
Int J Antimicrob Agents; 2001 Feb; 17(2):143-6. PubMed ID: 11165119
[TBL] [Abstract][Full Text] [Related]
10. In-vitro antibacterial activity of L-105, a new cephalosporin.
Hikida M; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1986 Nov; 18(5):585-91. PubMed ID: 3492485
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ME1228, a new parenteral cephalosporin.
Neu HC; Saha G; Chin NX
Antimicrob Agents Chemother; 1989 Aug; 33(8):1260-7. PubMed ID: 2802554
[TBL] [Abstract][Full Text] [Related]
12. Development of bacterial resistance to the third generation cephalosporins and their clinical use.
Kolár M; Látal T; Hájek V
J Chemother; 1999 Aug; 11(4):260-5. PubMed ID: 10465127
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates.
Washington JA; Jones RN; Allen SD; Gerlach EH; Koontz FP; Murray PR; Pfaller MA; Erwin ME
Antimicrob Agents Chemother; 1991 Jul; 35(7):1508-11. PubMed ID: 1929319
[TBL] [Abstract][Full Text] [Related]
14. [Specificities of antibacterial activity of zwitterionic 7-methoxyimino cephems (cephalosporins of fourth generation].
Pechère JC
Pathol Biol (Paris); 1996 Feb; 44(2):99-105. PubMed ID: 8761594
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of cephalosporins, 2-isocephems, and 2-oxaisocephems with C-3' or C-7 catechol or related aromatics.
Tsuji K; Tsubouchi H; Yasumura K; Matsumoto M; Ishikawa H
Bioorg Med Chem; 1996 Dec; 4(12):2135-49. PubMed ID: 9022977
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases.
Sakurai Y; Yoshida Y; Saitoh K; Nemoto M; Yamaguchi A; Sawai T
J Antibiot (Tokyo); 1990 Apr; 43(4):403-10. PubMed ID: 2112533
[TBL] [Abstract][Full Text] [Related]
17. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
18. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antibacterial activity of the new semisynthetic cephalosporin cefpirome.
Mitsukude M; Inoue M; Mitsuhashi S
Arzneimittelforschung; 1989 Jan; 39(1):26-30. PubMed ID: 2785801
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo antibacterial activities of E1040, a new cephalosporin with potent antipseudomonal activity.
Hiruma R; Otsuki M; Tashima M; Obana Y; Nishino T
J Antimicrob Chemother; 1990 Dec; 26(6):769-81. PubMed ID: 2127928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
